Despite the positive reception that the Street afforded Intercept Pharmaceuticals Inc. and Kythera Biopharmaceuticals Inc., which each priced their initial public offerings (IPOs) at the top end of their ranges on the same day back in October, the bullish response to those two biotech offerings was not, it turned out to be, a harbinger for others to quickly follow suit. Read More
Thirty-five million people in the U.S. suffer from a stubborn fungal infection of the nail and nail bed called onychomycosis. Patients are typically treated by debridement to improve the appearance of the nail, but options for actually eliminating the fungus are lacking. Read More
The new £100 million (US$160 million) Wales Life Sciences Fund (WLSF) is poised to make its first investment after appointing biotech veteran Chris Evans to run the fund and pulling together a supporting cast of nine seasoned industry experts to manage its portfolio. Read More
Pharma's productivity woes have spawned a new UK company, Avillion LLP, which is offering to plug between $50 million and $100 million into the co-development of Phase III assets. Read More
• Addex Therapeutics SA, of Geneva, reported that its product candidate dipraglurant showed robust and dose-dependent reduction in severity of dystonia-like attacks in a mouse model. Read More
• OncoPep Inc., of Boston, said it started a Phase I/IIa trial testing PVX-410, a multipeptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma. Read More
• Cumberland Pharmaceuticals Inc., of Nashville, Tenn., said it entered an exclusive agreement with Indonesia's PT. SOHO Industri Pharmasi for the registration and commercialization of Caldolor (ibuprofen) injection, which is used to treat pain and fever in the hospital setting. Read More
